PCA
TXMD icon

Personal Capital Advisors’s TherapeuticsMD TXMD Stock Holding History

Personal Capital Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-260
Closed -$5K – 492
2022
Q1 		$5K Sell
260
-1
-0.4% -$16 ﹤0.01% 493
2021
Q4 		$5K Sell
261
-1
-0.4% -$30 ﹤0.01% 549
2021
Q3 		$10K Sell
262
-2
-0.8% -$89 ﹤0.01% 497
2021
Q2 		$16K Buy
264
+2
+0.8% +$121 ﹤0.01% 486
2021
Q1 		$18K Buy
262
+2
+0.8% +$157 ﹤0.01% 475
2020
Q4 		$16K Hold
260
– – ﹤0.01% 457
2020
Q3 		$21K Hold
260
– – ﹤0.01% 414
2020
Q2 		$16K Buy
+260
New +$15.1K ﹤0.01% 361

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Personal Capital Advisors's TXMD Position: Q2 2022 in Review

Personal Capital Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 260 shares — an estimated $5K sold.

Personal Capital Advisors first reported a position in TXMD in Q2 2020 and held it in 8 quarters. The position peaked at $21K in Q3 2020. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Personal Capital Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Personal Capital Advisors sold 260 TherapeuticsMD shares in Q2 2022, an estimated $5K.
  • Personal Capital Advisors first reported a position in TherapeuticsMD in Q2 2020 and held it in 8 quarters.
  • Personal Capital Advisors's TherapeuticsMD position peaked at $21K in Q3 2020.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Personal Capital Advisors's 13F filing for Q2 2022, filed 4 Aug 2022.